Risk of Venous Thrombosis in Antithrombin Deficiency: A Systematic Review and Bayesian Meta-analysis

Seminars in Thrombosis and Hemostasis

Volumn 44, Issue 4, 2018, Pages 315-326

  Croles, F Nanne ^a,b   Borjas Howard, Jaime ^b   Nasserinejad, Kazem ^c   Leebeek, Frank W G ^a   Meijer, Karina ^b  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c ERASMUS MC CANCER INSTITUTE   (Netherlands)

Author keywords

anticoagulants; antithrombin deficiency; Bayes theorem; meta analysis; venous thromboembolism

Indexed keywords

ANTITHROMBIN; ANTICOAGULANT AGENT;

ANTICOAGULANT THERAPY; ANTITHROMBIN DEFICIENCY; COCHRANE LIBRARY; EMBASE; HIGH RISK PATIENT; HUMAN; MEDLINE; META ANALYSIS; PRIORITY JOURNAL; RECURRENCE RISK; RECURRENT DISEASE; REVIEW; RISK FACTOR; SYSTEMATIC REVIEW; VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM; WEB OF SCIENCE; COMPLICATION; FEMALE; MALE; THROMBOPHILIA;

ANTICOAGULANTS; ANTITHROMBINS; FEMALE; HUMANS; MALE; RISK FACTORS; THROMBOPHILIA; VENOUS THROMBOSIS;

EID: 85042186927     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0038-1625983     Document Type: Review

References (54)

1. Egeberg O. Thrombophilia caused by inheritable deficiency of blood antithrombin. Scand J Clin Lab Invest: 1965; 17 92
2. Lane D. A. Kunz G. Olds R. J. Thein S. L. Molecular genetics of antithrombin deficiency. Blood Rev: 1996; 10 02 59 74
3. Mitsuguro M. Sakata T. Okamoto A., et al. Usefulness of antithrombin deficiency phenotypes for risk assessment of venous thromboembolism: type I deficiency as a strong risk factor for venous thromboembolism. Int J Hematol: 2010; 92 03 468 473
4. Luxembourg B. Pavlova A. Geisen C., et al. Impact of the type of SERPINC1 mutation and subtype of antithrombin deficiency on the thrombotic phenotype in hereditary antithrombin deficiency. Thromb Haemost: 2014; 111 02 249 257
5. Croles F. N. Nasserinejad K. Duvekot J. J. Kruip M. J. Meijer K. Leebeek F. W. Pregnancy, thrombophilia, and the risk of a first venous thrombosis: systematic review and bayesian meta-analysis. BMJ: 2017; 359 j4452
6. Konstantinides S. V. Torbicki A. Agnelli G., et al. Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J: 2014; 35 43 3033 3069, 3069a-3069k
7. Guyatt G. H. Akl E. A. Crowther M., et al. Executive summary: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest: 2012; 141 (2 Suppl): 7S 47S
8. Di Minno M. ND. Ambrosino P. Ageno W. Rosendaal F. Di Minno G. Dentali F. Natural anticoagulants deficiency and the risk of venous thromboembolism: a meta-analysis of observational studies. Thromb Res: 2015; 135 05 923 932
9. Wells G. ASB. O'Connell D. Peterson J., et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses. http://www.ohri.ca/programs/clinical-epidemiology/oxford.asp. Accessed October 5, 2015
10. Smith T. C. Spiegelhalter D. J. Thomas A. Bayesian approaches to random-effects meta-analysis: a comparative study. Stat Med: 1995; 14 24 2685 2699
11. R-Core-Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. http://www.R-project.org/. Accessed July 1, 2016
12. Plummer M. JAGS: A program for analysis of Bayesian graphical models using Gibbs sampling. Proceedings of the 3rd International Workshop on Distributed Statistical Computing 2003;124
13. Alhenc-Gelas M. Plu-Bureau G. Hugon-Rodin J. Picard V. Horellou M. H.; GFHT study group on Genetic Thrombophilia. Thrombotic risk according to SERPINC1 genotype in a large cohort of subjects with antithrombin inherited deficiency. Thromb Haemost: 2017; 117 06 1040 1051
14. Brouwer J. L. Veeger N. J. Kluin-Nelemans H. C. van der Meer J. The pathogenesis of venous thromboembolism: evidence for multiple interrelated causes. Ann Intern Med: 2006; 145 11 807 815
15. Bucciarelli P. Passamonti S. M. Biguzzi E., et al. Low borderline plasma levels of antithrombin, protein C and protein S are risk factors for venous thromboembolism. J Thromb Haemost: 2012; 10 09 1783 1791
16. Bucciarelli P. Rosendaal F. R. Tripodi A., et al. Risk of venous thromboembolism and clinical manifestations in carriers of antithrombin, protein C, protein S deficiency, or activated protein C resistance: a multicenter collaborative family study. Arterioscler Thromb Vasc Biol: 1999; 19 04 1026 1033
17. Chougule A. Rajpal S. Ahluwalia J., et al. Coagulation factor VIII, IX and XI levels in north Indian patients with venous thromboembolism: first study from India. Blood Coagul Fibrinolysis: 2016; 27 01 58 63
18. Cogo A. Lensing A. WA. Prandoni P., et al. Relevance of inherited risk factors in young patients with deep-vein thrombosis. Clin Appl Thromb Hemost: 1996; 2 01 55 59
19. Cohen W. Castelli C. Alessi M. C., et al. ABO blood group and von ospholipid factor levels partially explained the incomplete penetrance of congenital thrombophilia. Arterioscler Thromb Vasc Biol: 2012; 32 08 2021 2028
20. De Stefano V. Leone G. Mastrangelo S., et al. Clinical manifestations and management of inherited thrombophilia: retrospective analysis and follow-up after diagnosis of 238 patients with congenital deficiency of antithrombin III, protein C, protein S. Thromb Haemost: 1994; 72 03 352 358
21. Di Minno M. N. Dentali F. Veglia F. Russolillo A. Tremoli E. Ageno W. Antithrombin levels and the risk of a first episode of venous thromboembolism: a case-control study. Thromb Haemost: 2013; 109 01 167 169
22. Folsom A. R. Aleksic N. Wang L. Cushman M. Wu K. K. White R. H. Protein C, antithrombin, and venous thromboembolism incidence: a prospective population-based study. Arterioscler Thromb Vasc Biol: 2002; 22 06 1018 1022
23. Koster T. Rosendaal F. R. Briët E., et al. Protein C deficiency in a controlled series of unselected outpatients: an infrequent but clear risk factor for venous thrombosis (Leiden Thrombophilia Study). Blood: 1995; 85 10 2756 2761
24. Mahmoodi B. K. Brouwer J. L. Ten Kate M. K., et al. A prospective cohort study on the absolute risks of venous thromboembolism and predictive value of screening asymptomatic relatives of patients with hereditary deficiencies of protein S, protein C or antithrombin. J Thromb Haemost: 2010; 8 06 1193 1200
25. Martinelli I. Mannucci P. M. De Stefano V., et al. Different risks of thrombosis in four coagulation defects associated with inherited thrombophilia: a study of 150 families. Blood: 1998; 92 07 2353 2358
26. Mateo J. Oliver A. Borrell M. Sala N. Fontcuberta J. Increased risk of venous thrombosis in carriers of natural anticoagulant deficiencies. Results of the family studies of the Spanish Multicenter Study on Thrombophilia (EMET study). Blood Coagul Fibrinolysis: 1998; 9 01 71 78
27. Okumus G. Kiyan E. Arseven O., et al. Hereditary thrombophilic risk factors and venous thromboembolism in Istanbul, Turkey: the role in different clinical manifestations of venous thromboembolism. Clin Appl Thromb Hemost: 2008; 14 02 168 173
28. Rossi E. Ciminello A. Za T. Betti S. Leone G. De Stefano V. In families with inherited thrombophilia the risk of venous thromboembolism is dependent on the clinical phenotype of the proband. Thromb Haemost: 2011; 106 04 646 654
29. Sakata T. Okamoto A. Mannami T. Matsuo H. Miyata T. Protein C and antithrombin deficiency are important risk factors for deep vein thrombosis in Japanese. J Thromb Haemost: 2004; 2 03 528 530
30. Sanson B. J. Simioni P. Tormene D., et al. The incidence of venous thromboembolism in asymptomatic carriers of a deficiency of antithrombin, protein C, or protein S: a prospective cohort study. Blood: 1999; 94 11 3702 3706
31. Shen M. C. Lin J. S. Tsay W. Protein C and protein S deficiencies are the most important risk factors associated with thrombosis in Chinese venous thrombophilic patients in Taiwan. Thromb Res: 2000; 99 05 447 452
32. Suchon P. Al Frouh F. Henneuse A., et al. Risk factors for venous thromboembolism in women under combined oral contraceptive. The PILl Genetic RIsk Monitoring (PILGRIM) Study. Thromb Haemost: 2016; 115 01 135 142
33. Tormene D. Fortuna S. Tognin G., et al. The incidence of venous thromboembolism in carriers of antithrombin, protein C or protein S deficiency associated with the HR2 haplotype of factor V: a family cohort study. J Thromb Haemost: 2005; 3 07 1414 1420
34. Vossen C. Y. Conard J. Fontcuberta J., et al. Risk of a first venous thrombotic event in carriers of a familial thrombophilic defect. The European Prospective Cohort on Thrombophilia (EPCOT). J Thromb Haemost: 2005; 3 03 459 464
35. Vossen C. Y. Conard J. Fontcuberta J., et al. Familial thrombophilia and lifetime risk of venous thrombosis. J Thromb Haemost: 2004; 2 09 1526 1532
36. Baglin T. Luddington R. Brown K. Baglin C. Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors: prospective cohort study. Lancet: 2003; 362 (9383): 523 526
37. Brouwer J. L. Lijfering W. M. Ten Kate M. K. Kluin-Nelemans H. C. Veeger N. J. van der Meer J. High long-term absolute risk of recurrent venous thromboembolism in patients with hereditary deficiencies of protein S, protein C or antithrombin. Thromb Haemost: 2009; 101 01 93 99
38. De Stefano V. Simioni P. Rossi E., et al. The risk of recurrent venous thromboembolism in patients with inherited deficiency of natural anticoagulants antithrombin, protein C and protein S. Haematologica: 2006; 91 05 695 698
39. Di Minno M. N. Dentali F. Lupoli R. Ageno W. Mild antithrombin deficiency and risk of recurrent venous thromboembolism: a prospective cohort study. Circulation: 2014; 129 04 497 503
40. Kearon C. Julian J. A. Kovacs M. J., et al. ELATE Investigators. Influence of thrombophilia on risk of recurrent venous thromboembolism while on warfarin: results from a randomized trial. Blood: 2008; 112 12 4432 4436
41. Vossen C. Y. Walker I. D. Svensson P., et al. Recurrence rate after a first venous thrombosis in patients with familial thrombophilia. Arterioscler Thromb Vasc Biol: 2005; 25 09 1992 1997
42. Weingarz L. Schindewolf M. Schwonberg J., et al. Thrombophilia and risk of VTE recurrence according to the age at the time of first VTE manifestation. Vasa: 2015; 44 04 313 323
43. Prandoni P. Noventa F. Ghirarduzzi A., et al. The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients. Haematologica: 2007; 92 02 199 205
44. Taliani M. R. Becattini C. Agnelli G., et al. Warfarin Optimal Duration Italian Trial (WODIT) Investigators. Duration of anticoagulant treatment and recurrence of venous thromboembolism in patients with and without thrombophilic abnormalities. Thromb Haemost: 2009; 101 03 596 598
45. Santamaria M. G. Agnelli G. Taliani M. R., et al. Warfarin Optimal Duration Italian Trial (WODIT) Investigators. Thrombophilic abnormalities and recurrence of venous thromboembolism in patients treated with standardized anticoagulant treatment. Thromb Res: 2005; 116 04 301 306
46. Naess I. A. Christiansen S. C. Romundstad P. Cannegieter S. C. Rosendaal F. R. Hammerstrom J. Incidence and mortality of venous thrombosis: a population-based study. J Thromb Haemost: 2007; 5 04 692 699
47. Mishra M. N. Bedi V. S. Prevalence of common thrombophilia markers and risk factors in Indian patients with primary venous thrombosis. Sao Paulo Med J: 2010; 128 05 263 267
48. Heijboer H. Brandjes D. P. Büller H. R. Sturk A. ten Cate J. W. Deficiencies of coagulation-inhibiting and fibrinolytic proteins in outpatients with deep-vein thrombosis. N Engl J Med: 1990; 323 22 1512 1516
49. Bombeli T. Basic A. Fehr J. Prevalence of hereditary thrombophilia in patients with thrombosis in different venous systems. Am J Hematol: 2002; 70 02 126 132
50. Higgins J. PT. Green S., eds. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration: 2011;. Available from http://handbook.cochrane.org
51. Rossi E. Za T. Ciminello A. Leone G. De Stefano V. The risk of symptomatic pulmonary embolism due to proximal deep venous thrombosis differs in patients with different types of inherited thrombophilia. Thromb Haemost: 2008; 99 06 1030 1034
52. Kearon C. Akl E. A. Ornelas J., et al. Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. Chest: 2016; 149 02 315 352
53. Howard L. S. Hughes R. J. NICE guideline: management of venous thromboembolic diseases and role of thrombophilia testing. Thorax: 2013; 68 04 391 393
54. Iorio A. Kearon C. Filippucci E., et al. Risk of recurrence after a first episode of symptomatic venous thromboembolism provoked by a transient risk factor: a systematic review. Arch Intern Med: 2010; 170 19 1710 1716